Patents by Inventor David Kanne
David Kanne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11040053Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: GrantFiled: October 21, 2019Date of Patent: June 22, 2021Assignee: CHINOOK THERAPEUTICS, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
-
Patent number: 10906930Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.Type: GrantFiled: October 28, 2016Date of Patent: February 2, 2021Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AGInventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Jeffrey McKenna, Stephen M. Canham, Chudi Obioma Ndubaku
-
Publication number: 20200179431Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: ApplicationFiled: October 21, 2019Publication date: June 11, 2020Applicant: ADURO BIOTECH, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, JR.
-
Patent number: 10449211Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: GrantFiled: March 9, 2016Date of Patent: October 22, 2019Assignee: ADURO BIOTECH, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
-
Publication number: 20190062365Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.Type: ApplicationFiled: October 28, 2016Publication date: February 28, 2019Applicants: ADURO BIOTECH, INC., NOVARTIS AGInventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Kelsey GAUTHIER, Laura Hix GLICKMAN, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, Jr., Jeffrey McKENNA, Stephen M. CANHAM, Chudi Obioma NDUBAKU
-
Publication number: 20180369268Abstract: The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases.Type: ApplicationFiled: December 16, 2016Publication date: December 27, 2018Applicant: ADURO BIOTECH, INC.Inventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, JR.
-
Publication number: 20180064745Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: ApplicationFiled: March 9, 2016Publication date: March 8, 2018Applicant: ADURO BIOTECH, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
-
Publication number: 20180028553Abstract: Methods and compositions for treating cancer by intratumorally administering a stimulator of interferon genes (STING) agonist are disclosed herein.Type: ApplicationFiled: October 13, 2017Publication date: February 1, 2018Inventors: Thomas F. Gajewski, Seng-ryong Woo, Leticia Corrales, Thomas W. Dubensky, Jr., David Kanne, Meredith Lai Ling Leong, Laura Hix Glickman, Edward Emile Lemmens
-
Publication number: 20160287623Abstract: Methods and compositions for treating cancer by intratumorally administering a stimulator of interferon genes (STING) agonist are disclosed herein. In some embodiments, there are provided compositions and methods concerning methods for treating cancer in a subject comprising administering to the subject an effective amount of a stimulator of interferon genes (STING) agonist, wherein the STING agonist is administered intratumorally.Type: ApplicationFiled: November 19, 2014Publication date: October 6, 2016Inventors: Thomas F. Gajewski, Seng-ryong Woo, Leticia Corrales, Thomas W. Dubensky, Jr., David Kanne, Meredith Lai Ling Leong, Laura Hix Glickman, Edward Emile Lemmens
-
Publication number: 20120071513Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.Type: ApplicationFiled: November 28, 2011Publication date: March 22, 2012Applicant: COMPASS PHARMACEUTICALS LLCInventors: David Kanne, John Ward, Gary Look, X. Michael Wang, Diva Chan, Tina Lee, Donald R. James, Richard Gless, John Schullek, Charles Vacin
-
Publication number: 20110178087Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.Type: ApplicationFiled: March 30, 2011Publication date: July 21, 2011Applicant: Compass Pharmaceuticals LLC.Inventors: David Kanne, John Ward, Gary Look, X. Michael Wang, Diva Chan, Tina Lee, Donald R. James, Richard Gless, John Schullek, Charles Vacin
-
Publication number: 20090018145Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreating carcinomas) and mesotheliomas.Type: ApplicationFiled: October 18, 2005Publication date: January 15, 2009Applicant: Compass Pharmaceuticals LLCInventors: David Kanne, John Ward, Gary Look, X. Michael Wang, Diva Chan, Tina Lee, Donald R. James, Richard Gless, John Schullek, Charles Vacin
-
Patent number: 7188636Abstract: A portable enclosure apparatus is provided with a frame assembly having a bottom wall, an upper frame member and a single pair of vertical support members. The support members are easily length adjusted by a single user to vary the height of the system while in use. The frame assembly can be quickly disassembled for convenient storage and transport. A cover envelopes the frame assembly to complete the enclosure. A portable dust collector can be coupled with the cover to secure airborne debris moving into the enclosure.Type: GrantFiled: April 14, 2004Date of Patent: March 13, 2007Inventors: Steve Kanne, Brian Kenkel, David Kanne, Jimmy Judd